Incyte Corp
Q1 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +6.33%.
Did INCY Beat Earnings? Q1 2025 Results
Incyte posted a convincing first-quarter beat in 2025, with revenue of $1.05 billion rising 19.5% year over year and non-GAAP diluted EPS of $1.16 clearing the $1.05 consensus estimate by 10.62%, as the company's flagship drug Jakafi delivered $709.41 million in net product revenue, a 24% year-over-year gain fueled by stronger paid demand across all indications and favorable tailwinds from the Inflation Reduction Act's Part D redesign. Opzelura added further momentum with $118.70 million in net product revenue, up 38% year over year, while newly launched Niktimvo generated $13.61 million in just its first two months on the market. The strong commercial performance prompted management to nudge full-year 2025 Jakafi guidance higher to $2.95 billion to $3.00 billion, with Opzelura guidance held at $630 million to $670 million as the company anticipates a pediatric atopic dermatitis approval in the second half of the year. Pipeline progress, including positive Phase 3 results for povorcitinib in hidradenitis suppurativa, reinforced confidence in Incyte's longer-term growth trajectory.
- Jakafi paid demand growth of 10% across all indications
- Positive impact of Part D redesign under the Inflation Reduction Act on Jakafi revenue
- Less de-stocking in Jakafi vs. Q1 2024 contributing 7% favorable impact
- Opzelura U.S. paid demand up 24% from new patient starts and refills in AD and vitiligo
- Opzelura ex-U.S. growth from continued uptake in Germany and France, plus recent launches in Italy and Spain
- Niktimvo successful commercial launch generating revenue in first two months
- Monjuvi/Minjuvi revenue growth from full quarter of U.S. sales vs. two months in Q1 2024 following February 2024 rights acquisition
“The double-digit revenue growth in the first quarter driven by the continued growth of Jakafi and Opzelura and the recent launch of Niktimvo, puts us on track to achieve our full year objectives.”
Incyte CEO, on the earnings call
Forward Guidance & Outlook
Incyte raised its full-year 2025 Jakafi net product revenue guidance to $2,950–$3,000 million from $2,925–$2,975 million. Opzelura full-year guidance remains at $630–$670 million (including anticipated pediatric atopic dermatitis approval in H2 2025). Other oncology net product revenues are guided at $415–$455 million. GAAP cost of product revenues is expected at 8.5%–9.0% of net product revenues. GAAP R&D expenses are guided at $1,930–$1,960 million, with Non-GAAP R&D at $1,780–$1,805 million (excluding $15 million for the Genesis collaboration). GAAP SG&A expenses are guided at $1,280–$1,310 million, with Non-GAAP SG&A at $1,160–$1,185 million. Multiple regulatory submissions and approvals are anticipated in H2 2025, including Opzelura for pediatric AD, Monjuvi for follicular lymphoma, and Zynyz for squamous cell anal carcinoma. Povorcitinib regulatory submissions for HS are planned. Phase 3 tafasitamab data in first-line DLBCL are expected in H2 2025.
INCY YoY Financials
INCY Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.